Itrazole Dosage/Direction for Use

Itraconazole is for oral administration and must be taken immediately after a meal for maximal absorption. The capsules must be swallowed whole.
Treatment schedules in adults for each indication are as follows: See Table 1.

Click on icon to see table/diagram/image

For skin, vulvovaginal and oropharyngeal infections, optimal clinical and mycological effects are reached 1 to 4 weeks after cessation of treatment and for nail infections, 6 to 9 months after the cessation of treatment. This is because elimination of Itraconazole from skin, nails and mucous membranes is slower than from plasma.
The length of treatment for systemic fungal infections should be dictated by the mycological and clinical response to therapy: See Table 2.

Click on icon to see table/diagram/image

Impaired absorption in AIDS and neutropenic patients may lead to low Itraconazole blood levels and lack of efficacy. In such cases, blood level monitoring and if necessary, an increase in Itraconazole dose to 200 mg twice daily, is indicated.
Special populations: Paediatrics: Clinical data on the use of Itraconazole Capsules in paediatric patients are limited. The use of Itraconazole capsules in paediatric patients is not recommended unless it is determined that the potential benefit outweighs the potential risks.
Elderly: Clinical data on the use of Itraconazole Capsules in elderly patients are limited. It is advised to use Itraconazole capsules in these patients only if it is determined that the potential benefit outweighs the potential risks. In general, it is recommended that the dose selection for an elderly patient should be taken into consideration, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Renal impairment: Limited data are available on the use of oral Itraconazole in patients with renal impairment. The exposure of Itraconazole may be lower in some patients with renal insufficiency. Caution should be exercised when this drug is administered in this patient population and adjusting the dose may be considered.
Hepatic impairment: Limited data are available on the use of oral Itraconazole in patients with hepatic impairment. Caution should be exercised when this drug is administered in this patient population.